Remarks: Sorafenib tosylate is the first listing of approved drugs targeting multiple targets, but also over the past decade is the only FDA approved drug for the treatment of renal cell carcinoma.
None of the products will be supplied to countries in which this could be in conflict with the existing patents. However the final responsibility lies with the Buyer.